Orchid Pharma Limited — Important, 12-02-2025: Financial Result Updates

**Consolidated Financials:** Orchid Pharma reported consolidated financial results for the third quarter and nine months of FY 2024-25, ending December 31, 2024.

**Revenue Growth:** The company recorded total revenue of ₹120.25 crore, reflecting a robust growth of 15% year-over-year. Factors contributing to this growth include increased demand for their pharmaceutical products and successful market expansion strategies.

**Profit and EPS:** Net profit for the period stood at ₹12.34 crore, up from ₹10.25 crore in the previous year, translating to an Earnings Per Share (EPS) of ₹2.50 compared to ₹2.05 a year earlier. This improvement is attributed to higher sales volume and effective cost management.

**Operational Costs:** Operational costs saw a modest increase of 5%, primarily due to strategic investments in R&D and marketing, indicating proactive efforts to enhance product offerings and market presence.

**Balance Sheet & Cash Flow Statement:** The balance sheet remains healthy, with total financial indebtedness of ₹73.44 crore and a default status of nil, suggesting effective debt management. Positive cash flow from operations supports ongoing investments.

**Strategic Position and Outlook:** The focus on innovation and market penetration is evident, with sentiments remaining optimistic regarding potential growth in both domestic and international markets. The management highlights ongoing discussions to optimize operational efficiency and enhance profitability.

**Investor Insight:** With strong revenue growth, improved profitability, and prudent financial management, Orchid Pharma offers a favorable opportunity for equity investors, suggesting a favorable stance on holding or potentially increasing investments.